Senti Biosciences, Inc.

Dynamics Special Purpose Corp (Nasdaq: DYNS), a blank-check company sponsored by Casdin Capital and Foresite Capital Management, filed an amended Form 8-K with the SEC on December 10, 2021 in connection with its proposed business combination with Senti Biosciences, Inc., a synthetic biology company developing gene circuit-based cell and gene therapies for oncology. DYNS completed its initial public offering in 2021, targeting the life sciences and biotechnology sector. At the time of filing, the SPAC was in the de-SPAC transaction process ahead of the merger closing, which was subsequently completed in 2022, resulting in Senti Biosciences becoming a publicly traded company. Sign up at SpacDesk for full filing history, deal timelines, and sponsor data on DYNS and hundreds of other SPACs.